Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Mise à jour : Il y a 4 ans
Référence : NCT00127881

Femme et Homme

Extrait

The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.


Critère d'inclusion

  • Mycosis fungoides ,Sezary Syndrome


Liens